| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by investing activities | 33,841 | 2,443 |
| Proceeds from exercise of options into ordinary shares | 629 | 327 |
| Proceeds from issuance of long-term debt | 0 | - |
| Proceeds from pre-funded warrant issuance, net of issuance costs | 3 | 3 |
| Proceeds from ordinary shares issuances, net of issuance costs | 7,970 | 0 |
| Net cash provided by financing activities | 8,602 | 330 |
| Increase (decrease) in cash and cash equivalents | -81,676 | -79,076 |
| Cash and cash equivalents at beginning of period | 173,062 | - |
| Cash and cash equivalents at end of period | 91,386 | - |
UroGen Pharma Ltd. (URGN)
UroGen Pharma Ltd. (URGN)